(Press-News.org) A new drug which offers a radically different approach to treating certain types of heart failure has been shown to improve cardiac function in heart failure patients in its first clinical trials.
Current treatments for heart failure are aimed at a wide range of targets, but omecamtiv mercabil is the first of a new class of drugs – called cardiac myosin activators – which target the motor proteins that cause muscle contraction. Cardiac myosin activators prolong the interaction between the motor proteins myosin and actin to prolong the contraction of the left ventricle, the heart chamber which pumps oxygenated blood out to the rest of the body.
Rather than make the heart beat more often, omecamtiv mercabil makes the heart muscles contract for longer, which increases the volume of blood the heart pumps with each stroke.
The Phase II clinical trial – led by the University of Hull and reported in this week's Lancet – tested the drug for safety and effectiveness in 45 heart failure patients with impaired function of the left ventricle.
Although the drug increased the duration of left ventricular contraction and the amount of blood expelled, it did not increase the heart's energy expenditure, which means the heart was working more effectively and efficiently.
Professor John Cleland, from the University of Hull says: "The trial proves that the drug can be given safely to patients suffering from heart failure and shows that, at the correct doses and blood plasma concentrations, it can improve heart function and make the heart contract more effectively."
The drug had already been successfully tested with healthy volunteers, but the Hull trial was the first to test the drug with heart failure patients. Currently, the drug has to be given by infusion into a vein but a capsule is being developed that can be taken by mouth. All patients taking part in the double-blind, placebo, crossover trial were stable, and most were taking accepted treatments for the condition such as ACE inhibitors and blockers.
"This initial trial was very promising and further larger-scale studies of the drug are already underway," says Professor Cleland. "We need to see whether the improvements in cardiac function translate into real benefits for patients, in terms of their symptoms and quality of life, and whether it can impact on mortality and morbidity."
### END
Not faster, but longer -- new drug changes beat in treating heart failure
2011-08-19
ELSE PRESS RELEASES FROM THIS DATE:
Single flexible sigmoidoscopy screening associated with reduced colorectal cancer
2011-08-19
A single flexible sigmoidoscopy screening between the ages of 55-64 years is associated with a lower level of colorectal cancer (CRC) incidence and mortality, according to a study published online August 18 in the Journal of the National Cancer Institute.
Multiple randomized controlled trials have shown that fecal occult blood testing (FOBT) in CRC screening can reduce the mortality rate of patients diagnosed with CRC. Observational studies and a prior, randomized trial from the U.K., known as SCORE have shown a reduction in incidence and mortality for cancer in the ...
Complex choices in Medicare Advantage program may overwhelm seniors, study finds
2011-08-19
Boston, MA (August 18, 2011) — In health care, more choice may not always lead to better choices, particularly for the elderly.
In a new study, researchers from Harvard Medical School's Department of Health Care Policy found that the large variety of managed care plans offered by the Medicare Advantage program may be counter-productive. Elderly patients, particularly those with low cognitive ability, often make poor decisions—or no decisions at all—when faced with an overwhelming number of complex insurance choices. Ironically, those with impaired cognition may benefit ...
Study finds coronary calcium beats C-reactive protein for predicting heart attack and stroke risk
2011-08-19
The presence of calcium in coronary arteries is a much better predictor of heart attack and stroke than C-reactive protein among people with normal levels of LDL cholesterol, according to a study of more than 2,000 people led by a Johns Hopkins heart specialist.
Results of the study, published in the August 19, 2011 issue of The Lancet, have important implications for deciding whether cholesterol-lowering statin medication should be prescribed for people who have heart disease risk factors but normal levels of LDL, the so-called "bad" cholesterol. An estimated 6 million ...
Johns Hopkins education leaders call for radical transformation in graduate biomedical curriculum
2011-08-19
Leaders in biomedical education at Johns Hopkins University School of Medicine are calling for a radical new approach to post-graduate training in the life sciences to address significant challenges, including an avalanche of new discoveries in the last decade and the need to transcend traditional departmental boundaries to understand biological processes at multiple levels.
In a Leading Edge commentary published in the August 19, 2011 edition of Cell, the authors present a new model for biomedical education that would break down current silos of particular disciplines, ...
Public radio exposes injustice
2011-08-19
Malawian villagers have found an unlikely platform to expose injustice and abuse of power and bring their leaders to task, according to research funded by the Economic and Social Research Council (ESRC). Malawi's public radio station broadcasts are providing an alternative programme of news stories. The programme features contributions by ordinary Malawians, highlighting their everyday experiences of abuse and violation.
In a country where radio is the main form of mass media, the daily programme broadcast in Chichewa, the language spoken by most Malawians, has become ...
Cancer stem cells made, not born
2011-08-19
In cancer, tumors aren't uniform: they are more like complex societies, each with a unique balance of cancer cell types playing different roles. Understanding this "social structure" of tumors is critical for treatment decisions in the clinic because different cell types may be sensitive to different drugs. A common theory is that tumors are a hierarchical society, in which all cancer cells descend from special self-renewing cancer stem cells. This view predicts that killing the cancer stem cells might suffice to wipe out a cancer.
New findings by scientists at the Broad ...
UCI researchers chart long-shrouded glacial reaches of Antarctica
2011-08-19
Irvine, Calif. — A vast network of previously unmapped glaciers on the move from thousands of miles inland to the Antarctic coast has been charted for the first time by UC Irvine scientists (http://www.ess.uci.edu/). The findings will be critical to tracking future sea rise from climate change.
"This is like seeing a map of all the oceans' currents for the first time. It's a game changer for glaciology," said UCI earth system science professor Eric Rignot, lead author of a paper on the ice flow published online today in Science Express. "We're seeing amazing flows from ...
Molecular meet and greet
2011-08-19
Boston, Mass. (Aug. 19, 2011)—Researchers at Harvard Medical School have discovered that structural elements in the cell play a crucial role in organizing the motion of cell-surface receptors, proteins that enable cells to receive signals from other parts of the organism.
This discovery, published in the Aug. 19 issue of the journal Cell, fills a fundamental gap in the understanding of how cells relate to biochemical signals, including pharmaceuticals, and could have profound implications for drug development and the treatment of cancer and other diseases.
The findings ...
Kidney drugs hampered by high blood phosphate
2011-08-19
Washington, DC (August 18, 2011) — High blood phosphate levels can set chronic kidney disease (CKD) patients on a rapid path to kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). To make matters worse, phosphate appears to interfere with the effectiveness of important kidney medications.
The kidneys of patients with CKD cannot efficiently get rid of wastes such as excess phosphate in the blood. As a result, the kidneys become overloaded with phosphate. Carmine Zoccali, MD (CNR-IBIM, Clinical Epidemiology ...
New 'bionic' leg gives amputees a natural gait
2011-08-19
A new lower-limb prosthetic developed at Vanderbilt University allows amputees to walk without the leg-dragging gait characteristic of conventional artificial legs.
The device uses the latest advances in computer, sensor, electric motor and battery technology to give it bionic capabilities: It is the first prosthetic with powered knee and ankle joints that operate in unison. It comes equipped with sensors that monitor its user's motion. It has microprocessors programmed to use this data to predict what the person is trying to do and operate the device in ways that facilitate ...